Lil­ly plans for Zep­bound la­bel ex­pan­sion in­to sleep ap­nea in mid-2024 on back of Phase 3 win

Eli Lil­ly’s weight loss drug Zep­bound hit the pri­ma­ry end­points in two Phase 3 tri­als for adults with ob­struc­tive sleep ap­nea …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.